Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 198)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ethanol |
Approved |
Phase 4 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
2 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
3 |
|
Sildenafil |
Approved, Investigational |
Phase 4 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
4 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 4 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
5 |
|
Tetracycline |
Approved, Vet_approved, Withdrawn |
Phase 4 |
|
60-54-8 |
5353990 |
Synonyms:
(4S,4AS,5as,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Abramycin
Achromycin
ACHROMYCIN V
Anhydrotetracycline
CYCLOPAR
Deschlorobiomycin
E701
ECONOMYCIN
Liquamycin
NSC-108579
PANMYCI DONT CAREIQUAMYCIN
PANMYCIN
Sumycin
|
SUPRAMYCIN
SUSTAMYCIN
TC
TETRABID ORGANON
Tetracyclin
TETRACYCLINE
TÉTRACYCLINE
Tetracycline HCL
Tetracyclinum
TETRACYN
Tetrazyklin
Tsiklomitsin
VETQUAMYCIN
|
|
6 |
|
Sodium oxybate |
Approved |
Phase 4 |
|
502-85-2 |
23663870 |
Synonyms:
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT
NSC-84223
OXYBATE SODIUM
SODIUM OXYBATE
|
SODIUM OXYBUTYRATE
WY-3478
XYREM
|
|
7 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
8 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
9 |
|
Garlic |
Approved, Nutraceutical |
Phase 4 |
|
8008-99-9 |
|
Synonyms:
ALLIUM SATIVUM
ALLIUM SATIVUM BULB
ALLIUM SATIVUM BULB EXTRACT
ALLIUM SATIVUM BULB POWDER
|
ALLIUM SATIVUM POWDER
B1233
GARLIC
|
|
10 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
11 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
12 |
|
Thiamine |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
70-16-6 |
1130 |
Synonyms:
[<sup>3</sup>H]-thiamine|[<sup>3</sup>H]vitamin B<sub>1</sub>
2-[3-[(4-AMINO-2-METHYL-PYRIMIDIN-5-YL)METHYL]-4-METHYL-1-THIA-3-AZONIACYCLOPENTA-2,4-DIEN-5-YL]ETHANOL
2-[3-[(4-AMINO-2-METHYL-PYRIMIDIN-5-YL)METHYL]-4-METHYL-THIAZOL-5-YL]ETHANOL
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
ANEURIN
ANTIBERIBERI FACTOR
APATE DROPS
BEATINE
BEDOME
BEGIOLAN
BENERVA
BEQUIN
BERIN
BETALIN S
BETAXIN
BETHIAZINE
BEUION
BEVITEX
BEVITINE
BEWON
BIAMINE
BITHIAMIN
BIUNO
BIVATIN
BIVITA
CERNEVIT-12
CLOTIAMINA
ESKAPEN
|
ESKAPHEN
HYBEE
LIXA-BETA
METABOLIN
Mononitrate, thiamine
SLOWTEN
THD
THIADOXINE
THIAMIN
THIAMINAL
THIAMINE
Thiamine mononitrate
THIAMINE(1+)
THIAMINE(1+) ION
THIAMINIUM
Thiaminum
THIAMOL
THIAVIT
TIAMIDON
TIAMINA
TIAMINAL
TROPHITE
VETALIN S
VIB
VINOTHIAM
VITAMIN B 1
VITAMIN B1
VITANEURON
|
|
13 |
|
Antioxidants |
|
Phase 4 |
|
|
|
14 |
|
Protective Agents |
|
Phase 4 |
|
|
|
15 |
|
Ginkgo |
|
Phase 4 |
|
|
|
Synonyms:
B1260
EGB 761
EGB-761
GINKGO
GINKGO BILOBA EXTRACT
|
GINKGO BILOBA LEAF
GINKGO BILOBA LEAF DRY EXTRACT
GINKGO BILOBA LEAF EXTRACT
GINKGO BILOBA LEAF TINCTURE
|
|
16 |
|
Allyl sulfide |
|
Phase 4 |
|
|
|
17 |
|
Lemon Balm |
|
Phase 4 |
|
|
|
18 |
|
Hawthorn |
|
Phase 4 |
|
|
|
19 |
|
Diallyl Sulfide |
|
Phase 4 |
|
|
|
20 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
21 |
|
Central Nervous System Stimulants |
|
Phase 4 |
|
|
|
22 |
|
Dopamine Uptake Inhibitors |
|
Phase 4 |
|
|
|
23 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
24 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
25 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4 |
|
|
|
26 |
|
Citrate |
|
Phase 4 |
|
|
|
27 |
|
Lisdexamfetamine Dimesylate |
|
Phase 4 |
|
|
|
Synonyms:
ELVANSE
ELVANSE ADULT
LISDEXAMFETAMINE DIMESYLATE
LISDEXAMFETAMINE DIMETHANESULFONATE
LISDEXAMFETAMINE MESILATE
|
NRP104
NRP-104
SPD489
SPD-489
VYVANSE
|
|
28 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
29 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
30 |
|
Antiprotozoal Agents |
|
Phase 4 |
|
|
|
31 |
|
Antiparasitic Agents |
|
Phase 4 |
|
|
|
32 |
|
Antimalarials |
|
Phase 4 |
|
|
|
33 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
34 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
35 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
36 |
|
Complement System Proteins |
|
Phase 4 |
|
|
|
37 |
|
Complement C1s |
|
Phase 4 |
|
|
|
38 |
|
Complement C1 Inhibitor Protein |
|
Phase 4 |
|
|
|
39 |
|
Complement C1 Inactivator Proteins |
|
Phase 4 |
|
|
|
40 |
|
Vitamins |
|
Phase 4 |
|
|
|
41 |
|
Folate |
|
Phase 4 |
|
|
|
42 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
43 |
|
Trace Elements |
|
Phase 4 |
|
|
|
44 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
45 |
|
Micronutrients |
|
Phase 4 |
|
|
|
46 |
|
Vitamin B1 |
|
Phase 4 |
|
|
|
47 |
|
Thiamin |
|
Phase 4 |
|
|
|
48 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
49 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
50 |
|
Anesthetics |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 185)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome. |
Unknown status |
NCT01584934 |
Phase 4 |
Sodium oxybate;Placebo |
2 |
The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing |
Unknown status |
NCT01368718 |
Phase 4 |
|
3 |
High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study |
Unknown status |
NCT01926132 |
Phase 4 |
ascorbic acid 10g/20ml;Normal Saline 150ml |
4 |
A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation |
Unknown status |
NCT03542721 |
Phase 4 |
DA-5515;Placebo of DA-5515 |
5 |
Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention |
Completed |
NCT00860236 |
Phase 4 |
|
6 |
Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate |
Completed |
NCT02055898 |
Phase 4 |
Sodium Oxybate |
7 |
Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome. |
Completed |
NCT00598585 |
Phase 4 |
Sildenafil (Viagra);Placebo |
8 |
Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study |
Completed |
NCT01071044 |
Phase 4 |
Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg" |
9 |
The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment |
Completed |
NCT01318356 |
Phase 4 |
Doxycycline;Placebo |
10 |
A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection |
Recruiting |
NCT04705831 |
Phase 4 |
Ruconest |
11 |
PBC Induced Fatigue Treated With Thiamine (PIFT) - The Effect of Oral Thiamine Supplement in 4 Weeks to Patients With Primary Biliary Cholangitis (PBC) and Chronic Fatigue. A Randomised Placebo Controlled Crossover Study |
Recruiting |
NCT04893993 |
Phase 4 |
Thiamine;Placebo |
12 |
A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
Not yet recruiting |
NCT04622293 |
Phase 4 |
Solriamfetol Oral Tablet [Sunosi];Placebo |
13 |
Post-COVID-19 Chronic Fatigue Syndrome |
Not yet recruiting |
NCT05642923 |
Phase 4 |
Synthetic Vitamin B1 |
14 |
Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome. |
Terminated |
NCT00498485 |
Phase 4 |
Placebo;Sodium Oxybate |
15 |
Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome. |
Unknown status |
NCT01907711 |
Phase 2, Phase 3 |
|
16 |
A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome |
Completed |
NCT00375973 |
Phase 2, Phase 3 |
Duloxetine;Placebo |
17 |
Cytokine Inhibition in Chronic Fatigue Syndrome Patients |
Completed |
NCT02108210 |
Phase 2, Phase 3 |
Anakinra;Placebo |
18 |
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study. |
Completed |
NCT00848692 |
Phase 2, Phase 3 |
Rituximab;Saline (NaCl 0,9 %) (placebo) |
19 |
A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) |
Completed |
NCT00215800 |
Phase 3 |
Ampligen |
20 |
B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment. |
Completed |
NCT02229942 |
Phase 3 |
Rituximab;Placebo |
21 |
Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue |
Completed |
NCT01742013 |
Phase 3 |
GCJBP Laennec Inj.;Placebo |
22 |
A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS. |
Completed |
NCT02063126 |
Phase 2, Phase 3 |
|
23 |
Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors |
Completed |
NCT01281904 |
Phase 2, Phase 3 |
|
24 |
A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness |
Completed |
NCT02865460 |
Phase 3 |
Ubiquinol;Placebo |
25 |
The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis. |
Completed |
NCT02315872 |
Phase 3 |
ACTH;Placebo |
26 |
Adjunctive Treatment With Pramipexole for Anhedonic Depression Symptoms in Depression - PRIME-PRAXOL |
Not yet recruiting |
NCT05355337 |
Phase 3 |
Pramipexole;Placebo |
27 |
Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula |
Unknown status |
NCT01966276 |
Phase 2 |
Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos |
28 |
Phase 1 + 2a Proof of Concept Study of Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) |
Unknown status |
NCT01793415 |
Phase 1, Phase 2 |
IodoCarb (r) |
29 |
High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome - A Sino-Austrian Cooperation Randomized Controlled Trial(RCT) on Heart Rate Variability |
Unknown status |
NCT02924831 |
Phase 2 |
|
30 |
Effects of Iron Therapy in Patients With Chronic Fatigue and IBD |
Unknown status |
NCT02517151 |
Phase 2 |
Ferric carboxymaltose;Placebo |
31 |
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome |
Completed |
NCT03674541 |
Phase 2 |
Pyridostigmine Bromide;Placebo |
32 |
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome |
Completed |
NCT00540254 |
Phase 1, Phase 2 |
|
33 |
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) |
Completed |
NCT00478465 |
Phase 1, Phase 2 |
valganciclovir |
34 |
Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome |
Completed |
NCT03613129 |
Phase 1, Phase 2 |
CT38 |
35 |
Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months |
Completed |
NCT02444091 |
Phase 2 |
Cyclophosphamide |
36 |
The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial |
Completed |
NCT01040429 |
Phase 2 |
Clonidine;Lactose capsula |
37 |
Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome: Randomized Controlled Clinical Trial |
Completed |
NCT01512342 |
Phase 2 |
|
38 |
B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment |
Completed |
NCT01156909 |
Phase 2 |
Rituximab |
39 |
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement |
Recruiting |
NCT04542161 |
Phase 2 |
NAC 900mg/day;NAC 3600mg/day;NAC 0mg/day (Placebo) |
40 |
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments |
Recruiting |
NCT03844412 |
Phase 2 |
5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Nortriptyline;Placebo cream;Placebo pill |
41 |
Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer |
Recruiting |
NCT04049331 |
Phase 2 |
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED] |
42 |
Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? |
Recruiting |
NCT03983720 |
Phase 2 |
|
43 |
Fecal Microbiota Transplantation in Chronic Fatigue Syndrome - an RCT |
Active, not recruiting |
NCT03691987 |
Phase 2 |
|
44 |
A Double Blind Randomized Trial of Low-dose Naltrexone for Post-COVID Fatigue Syndrome |
Not yet recruiting |
NCT05430152 |
Phase 2 |
Low-Dose Naltrexone |
45 |
Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness |
Not yet recruiting |
NCT05367245 |
Phase 2 |
Cal-Mag Butyrate;Placebo |
46 |
An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome |
Terminated |
NCT00977171 |
Phase 2 |
Droxidopa |
47 |
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab. |
Terminated |
NCT01730495 |
Phase 2 |
Etanercept |
48 |
B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Severely Affected Chronic Fatigue Syndrome Patients. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment for Patients in WHO Performance Status III-IV |
Terminated |
NCT01156922 |
Phase 2 |
Rituximab |
49 |
Chronic Fatigue Syndrome: Correction of Mitochondrial Dysfunction by Conditioning Exercise and Nutraceutical Therapy. |
Withdrawn |
NCT01471652 |
Phase 2 |
Nutraceutical supplements;Placebo |
50 |
Autonomic Nervous System and Chronic Fatigue Syndrome |
Completed |
NCT00580619 |
Phase 1 |
L-NMMA trimethaphan;methyldopa |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
coenzyme Q10
Fish Oils
|
venlafaxine
Venlafaxine hydrochloride
|
|